Decoy Therapeutics Inc.
Organization details
- Legal name
- Decoy Therapeutics Inc.
- Former names
- Salarius Pharmaceuticals, Inc. Flex Pharma, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DCOY
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001615219
- EIN
- 46-5087339
Board of directors
-
Arnold C. Hanish · DirectorSince 2023
-
Bruce J. McCreedy Jr. · DirectorSince 2023
-
David J. Arthur · Director · Chief Executive OfficerSince 2023
-
Jonathan I. Lieber · DirectorSince 2023
-
Patricia G. Gauthier · DirectorSince 2026
-
Paul Lammers · DirectorSince 2023
-
Tess Burleson · DirectorSince 2023
-
William K. McVicar · DirectorSince 2023
Chief executives
Director election results
Annual meeting of July 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.1%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Omeros Corporation Same sectorvia Arnold C. Hanish
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $19,750
- 2 purchases by 2 insiders
- Sold, last 12 months
- $17
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Tess Burleson Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | Jonathan I. Lieber Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | PIERCE FREDERICK II Officer (Chief Executive Officer) | Grant or award | +33,455 | — | — |
| Aug 31, 2026 | Arnold C. Hanish Director | Grant or award | +3,000 | — | — |
| Aug 31, 2026 | Rosenblum Mark J Officer (Chief Financial Officer) | Grant or award | +9,682 | — | — |
| Aug 31, 2026 | Paul Lammers Director | Grant or award | +2,000 | — | — |
| Aug 31, 2026 | William K. McVicar Director | Grant or award | +3,000 | — | — |
| Aug 31, 2026 | Hibner Barbara Louise Officer (Chief Scientific Officer) | Grant or award | +4,216 | — | — |
| Aug 31, 2026 | Marschel Peter Klaus Officer (Chief Business Officer) | Grant or award | +3,900 | — | — |
| Aug 31, 2026 | Patricia G. Gauthier Director | Grant or award | +2,000 | — | — |
| Dec 30, 2025 | Arnold C. Hanish Director | Open-market sale | −15 | $0.64 | $10 |
| Dec 30, 2025 | Arnold C. Hanish Director | Open-market sale | −12 | $0.64 | $8 |
| Nov 20, 2025 | Arnold C. Hanish Director | Open-market purchase | +5,000 | $0.75 | $3,750 |
| Nov 20, 2025 | Rosenblum Mark J Officer (Exec VP Finance, CFO) | Open-market purchase | +20,000 | $0.80 | $16,000 |
| Feb 13, 2023 | Rosenblum Mark J Officer (Exec VP Finance, CFO) | Grant or award | +6,432 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Decoy Therapeutics Inc.
Who is the CEO of Decoy Therapeutics Inc.?
David J. Arthur is Decoy Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Decoy Therapeutics Inc.'s board?
Decoy Therapeutics Inc.'s board has 8 directors: Arnold C. Hanish, Bruce J. McCreedy Jr., David J. Arthur, Jonathan I. Lieber, Patricia G. Gauthier, Paul Lammers, Tess Burleson and William K. McVicar.
Are Decoy Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Decoy Therapeutics Inc. insiders bought $19,750 of shares in 2 purchases and sold $17 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="decoy-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.